Effect of flaxseed supplementation on prostatic carcinoma in transgenic mice

Urology

Volumn 60, Issue 5, 2002, Pages 919-924

  Lin, Xu ^a   Gingrich, Jeffrey R ^b   Bao, Wenjun ^a   Li, Jie ^a   Haroon, Zishan A ^c   Demark Wahnefried, Wendy ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c SRI INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIGENIN; DNA NUCLEOTIDYLEXOTRANSFERASE;

ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DIET SUPPLEMENTATION; EVALUATION; HISTOLOGY; LINSEED; LUNG; LYMPH NODE; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CARCINOMA; RANDOMIZATION; SEMINAL VESICLE; TRANSGENIC MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DIET; DISEASE MODELS, ANIMAL; DRUG SCREENING ASSAYS, ANTITUMOR; FLAX; IN SITU NICK-END LABELING; KI-67 ANTIGEN; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PHYTOTHERAPY; PROSTATIC NEOPLASMS;

EID: 0036845770     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)01863-0     Document Type: Article

References (30)

1. Clinton S.K., Giovannucci E. Diet, nutrition, and prostate cancer. Ann Rev Nutr. 18:1998;413-440.
2. Giovannucci E. Epidemiologic characteristics of prostate cancer. Cancer. 75:1995;1766-1777.
3. Thompson LU: Flaxseed, ligans, and cancer, in Thompson LU, and Cunnane SC (Eds): Flaxseed in Human Nutrition. Chicago, AOCS Press, 1995, pp 219-236.
4. Schuurman A.G., van den Brandt P.A., Dorant E., et al. Association of energy and fat intake with prostate carcinoma risk. Cancer. 86:1999;1019-1027.
5. Gann P.H., Hennekens C.H., Sacks F.M., et al. Prospective study of plasma fatty acids and risk of prostate cancer. J Natl Cancer Inst. 8:1994;281-286.
6. Morton M.S., Chan P.S.F., Cheng C., et al. Lignans and isoflavonoids in plasma and prostatic fluid in men samples from Portugal, Hong Kong, and the United Kingdom . Prostate. 32:1997;122-128.
7. Hansen H.S. New biological and clinical roles for the n-6 and n-3 fatty acids. Nutr Rev. 52:1994;162-167.
8. Rose D.P. Dietary fatty acids and prevention of hormone-responsive cancer. Proc Soc Exp Biol Med. 216:1997;224-233.
9. Jenab M., Thompson L.U. The influence of flaxseed and lignans on colon carcinogenesis and beta-glucuronidase activity. Carcinogenesis. 17:1996;1343-1348.
10. Serraino M., Thompson L.U. The effect of flaxseed supplementation on the initiation and promotional stages of mammary tumorigenesis. Nutr Cancer. 17:1992;153-159.
11. Thompson L.U., Rickard S.E., Orcheson L.J., et al. Flaxseed and its lignan and oil components reduce mammary tumor growth at a late stage of carcinogenesis. Carcinogenesis. 17:1996;1373-1376.
12. Thompson L.U., Seidl M.M., Rickard S.E., et al. Antitumorigenic effect of a mammalian lignan precursor from flaxseed. Nutr Cancer. 26:1996;159-165.
13. Yan L., Yee J.A., Li D., et al. Dietary flaxseed supplementation and experimental metastasis of melanoma cells in mice. Cancer Lett. 124:1998;181-186.
14. Tou J.C., Chen J., Thompson L.U. Dose, timing, and duration of flaxseed exposure affect reproductive indices and sex hormone levels in rats. J Toxicol Environ Health. 56:1999;555-570.
15. Demark-Wahnefried W., Price D.T., Polascik T.J., et al. Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery exploring the effects on hormonal levels, prostate-specific antigen, and histopathologic features . Urology. 58:2001;47-52.
16. Lin X., Switzer B.R., Demark-Wahnefried W. Effect of mammalian lignans on growth prostate cancer cell lines. Anticancer Res. 21:2001;3995-4000.
17. Greenberg N.M., DeMayo F., Finegold M.J., et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci. 92:1995;3439-3443.
18. Gingrich J.R., Barrios R.J., Morton R.A., et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res. 56:1996;4096-4102.
19. Greenberg N.M., DeMayo F.J., Sheppard P.C., et al. The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol Endocrinol. 8:1994;230-239.
20. Gingrich J.R., Barrios R.J., Foster B.A., et al. Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer Prostatic Dis. 2:1999;70-75.
21. Hale L.P., Clark A.G., Li J., et al. Age-related thymic atrophy in the guinea pig. Develop Compar Immunol. 25:2001;509-518.
22. Duchrow M., Schluter C., Key G., et al. Cell proliferation-associated nuclear antigen defined by antibody Ki-67 a new kind of cell cycle-maintaining proteins . Arch Immunol Ther Exp. 43:1995;117-121.
23. Gerdes J., Li L., Schlueter C., et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol. 138:1991;867-873.
24. Gavrieli Y., Sherman Y., Ben-Sasson S.A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 119:1992;493-501.
25. Rozengurt E. Growth factors and cell proliferation. Curr Opin Cell Biol. 4:1992;161-165.
26. Thompson C.B. Apoptosis in the pathogenesis and treatment of disease. Science. 267:1995;1456-1462.
27. Aihara M., Scardino P.T., Truong L.D., et al. The frequency of apoptosis correlates with the prognosis of Gleason grade 3 adenocarcinoma of the prostate. Cancer. 75:1995;522-529.
28. Tou J.C., Chen J., Thompson L.U. Flaxseed and its lignan precursor, secoisolari-ciresinol diglycoside, affect pregnancy outcome and reproductive development in rats. J Nutr. 128:1998;1861-1868.
29. Horoszewicz J.S., Leong S.S., Kawinski E., et al. LNCaP model of human prostatic carcinoma. Cancer Res. 43:1983;1809-1818.
30. Raghow S., Kuliyev E., Steakley M., et al. Efficacious chemoprevention of primary prostate cancer by flutamide in an autochthonous transgenic model. Cancer Res. 60:2000;4093-4097.